LG121071 (original) (raw)
LG121071 (or LGD-121071) is a selective androgen receptor modulator (SARM) developed by Ligand Pharmaceuticals that was first described in 1999 and was the first orally active nonsteroidal androgen to be discovered. It is a tricyclic quinolone derivative, structurally distinct from other nonsteroidal AR agonists like andarine and enobosarm (ostarine). The drug acts as a high-affinity full agonist of the androgen receptor (AR) (Ki = 17 nM), with a potency and efficacy that is said to be equivalent to that of dihydrotestosterone (DHT). Unlike testosterone, but similarly to DHT, LG121071 and other nonsteroidal androgens cannot be potentiated by 5α-reductase in androgenic tissues (nor aromatized into estrogenic metabolites), and for this reason, show tissue-selective androgenic effects. In acc
| Property | Value |
|---|---|
| dbo:abstract | LG121071 (or LGD-121071) is a selective androgen receptor modulator (SARM) developed by Ligand Pharmaceuticals that was first described in 1999 and was the first orally active nonsteroidal androgen to be discovered. It is a tricyclic quinolone derivative, structurally distinct from other nonsteroidal AR agonists like andarine and enobosarm (ostarine). The drug acts as a high-affinity full agonist of the androgen receptor (AR) (Ki = 17 nM), with a potency and efficacy that is said to be equivalent to that of dihydrotestosterone (DHT). Unlike testosterone, but similarly to DHT, LG121071 and other nonsteroidal androgens cannot be potentiated by 5α-reductase in androgenic tissues (nor aromatized into estrogenic metabolites), and for this reason, show tissue-selective androgenic effects. In accordance, they are said to possess full anabolic activity with reduced androgenic activity, similarly to anabolic-androgenic steroids. The in vitro metabolism of LG121071 has been characterized in anticipation of its possible use as a doping agent. (en) |
| dbo:casNumber | 179897-70-2 |
| dbo:chEMBL | 390728 |
| dbo:pubchem | 9839132 |
| dbo:thumbnail | wiki-commons:Special:FilePath/LG-121071.svg?width=300 |
| dbo:wikiPageID | 51305888 (xsd:integer) |
| dbo:wikiPageLength | 5707 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1120576516 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:5α-reductase dbr:Potency_(pharmacology) dbr:Metabolite dbr:Androgen dbr:Androgen_receptor dbr:In_vitro dbr:Intrinsic_activity dbr:Quinolone dbc:Trifluoromethyl_compounds dbr:S-40503 dbr:Estrogen dbr:Oral_administration dbr:Enobosarm dbr:Full_agonist dbr:LG-120907 dbc:Antigonadotropins dbr:Ligand_Pharmaceuticals dbr:Acetothiolutamide dbr:Anabolic dbr:Andarine dbr:Nonsteroidal dbr:Bioavailable dbc:Quinolines dbc:Selective_androgen_receptor_modulators dbr:Affinity_(pharmacology) dbr:LGD-2226 dbr:LGD-3303 dbr:Dihydrotestosterone dbr:Metabolism dbr:Selective_androgen_receptor_modulator dbr:Tricyclic dbr:Anabolic-androgenic_steroid dbr:Aromatized dbr:Doping_agent |
| dbp:c | 15 (xsd:integer) |
| dbp:casNumber | 179897 (xsd:integer) |
| dbp:chembl | 390728 (xsd:integer) |
| dbp:chemspiderid | 8014851 (xsd:integer) |
| dbp:f | 3 (xsd:integer) |
| dbp:h | 15 (xsd:integer) |
| dbp:iupacName | 6 (xsd:integer) |
| dbp:n | 2 (xsd:integer) |
| dbp:o | 1 (xsd:integer) |
| dbp:pubchem | 9839132 (xsd:integer) |
| dbp:smiles | CCC1CCNC2=C1C=C3CCF (en) |
| dbp:stdinchi | 1 (xsd:integer) |
| dbp:stdinchikey | SZPPQFARTYXRKU-UHFFFAOYSA-N (en) |
| dbp:synonyms | LG-121071; LGD-121071 (en) |
| dbp:width | 225 (xsd:integer) |
| dbp:wikiPageUsesTemplate | dbt:Gastrointestinal-drug-stub dbt:Androgen_receptor_modulators dbt:Drugbox dbt:Genito-urinary-drug-stub dbt:Reflist dbt:Short_description |
| dct:subject | dbc:Trifluoromethyl_compounds dbc:Antigonadotropins dbc:Quinolines dbc:Selective_androgen_receptor_modulators |
| rdf:type | owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug |
| rdfs:comment | LG121071 (or LGD-121071) is a selective androgen receptor modulator (SARM) developed by Ligand Pharmaceuticals that was first described in 1999 and was the first orally active nonsteroidal androgen to be discovered. It is a tricyclic quinolone derivative, structurally distinct from other nonsteroidal AR agonists like andarine and enobosarm (ostarine). The drug acts as a high-affinity full agonist of the androgen receptor (AR) (Ki = 17 nM), with a potency and efficacy that is said to be equivalent to that of dihydrotestosterone (DHT). Unlike testosterone, but similarly to DHT, LG121071 and other nonsteroidal androgens cannot be potentiated by 5α-reductase in androgenic tissues (nor aromatized into estrogenic metabolites), and for this reason, show tissue-selective androgenic effects. In acc (en) |
| rdfs:label | LG121071 (en) |
| owl:sameAs | wikidata:LG121071 https://global.dbpedia.org/id/2cLYA |
| prov:wasDerivedFrom | wikipedia-en:LG121071?oldid=1120576516&ns=0 |
| foaf:depiction | wiki-commons:Special:FilePath/LG-121071.svg |
| foaf:isPrimaryTopicOf | wikipedia-en:LG121071 |
| is dbo:wikiPageRedirects of | dbr:LG-121071 dbr:LG-121,071 dbr:LG121,071 dbr:LGD-121,071 dbr:LGD-121071 dbr:LGD121,071 dbr:LGD121071 dbr:LGD_121,071 dbr:LGD_121071 dbr:LG_121,071 dbr:LG_121071 |
| is dbo:wikiPageWikiLink of | dbr:LG-121071 dbr:LG-121,071 dbr:LG121,071 dbr:LGD-121,071 dbr:LGD-121071 dbr:LGD121,071 dbr:LGD121071 dbr:LGD_121,071 dbr:LGD_121071 dbr:LG_121,071 dbr:LG_121071 |
| is foaf:primaryTopic of | wikipedia-en:LG121071 |
